Clinical trials: Pegfilgrastim
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00290667
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 338 sites in Czechia, France and 7 more
- Volunteers
- 586 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Lymphoma, Multiple Myeloma
Lonquek for Autologous Stem Cell Mobilization
The aim of this study is to evaluate the efficacy and tolerability of Lonquek which is a pegylated (long-acting) version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem cells for autologous…
- Trial name
- NCT02488382
- Testing
- Lonquek
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Sheba Medical Center
Lung Cancer
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00554463
- Testing
- Filgrastim, Pegfilgrastim, Etoposide
- Where
- 14 sites in United States
- Volunteers
- 5 people
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
Treatment for Elderly Patients With High Risk Breast Cancer
This open-label, multicenter study explored primary and secondary prophylaxis treatment with a single, fixed-dose, subcutaneous (SC) injection of pegfilgrastim in elderly subjects with high-risk breast cancer receiving…
- Trial name
- NCT00117910
- Testing
- pegfilgrastim
- Sponsor
- Amgen
Neutropenic Complications, Breast Neoplasms
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®
The study will assess the efficacy of LA-EP2006 compared to Neulasta® with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
- Conditions
- Neutropenic Complications, Breast Neoplasms, Chemotherapy-induced Neutropenia, Chemotherapeutic Toxicity
- Trial name
- PROTECT-1 (NCT01735175)
- Testing
- LA-EP2006, Neulasta®
- Where
- 41 sites in Brazil, India and 4 more
- Volunteers
- 316 people
- Sponsor
- Sandoz
Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00049595
- Testing
- bleomycin sulfate, filgrastim, pegfilgrastim
- Where
- 140 sites in Australia, Belgium and 11 more
- Volunteers
- 552 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Germ Cell Tumour
A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis
The treatment of germ cell tumours is considered to be one of the major successes in the area of cytotoxic chemotherapy. Even in patients who relapse after first line therapy, a durable remission rate of between 25% and 60% has…
- Trial name
- GAMMA (NCT01782339)
- Testing
- Combination Chemotherapy
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- Barts & The London NHS Trust
Diffuse Large B-Cell Lymphoma
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
Evaluation of impact of metformin on 2 year progression-free survival (PFS) rate in subjects with previously untreated DLBCL when added to standard induction therapy. (R-CHOP)
- Trial name
- DLBCL (NCT02531308)
- Testing
- Metformin, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Rush University Medical Center
Breast Cancer
Myocet Plus Endoxan for Older Patients With Breast Cancer
This study will evaluate the efficacy, safety and effect on quality of life of liposomal-encapsulated doxorubicin in combination with cyclophosphamide as first or second line treatment of older patients (≥ 70 years old) with…
- Trial name
- NCT01120171
- Testing
- Cyclophosphamide, Liposomal-encapsulated doxorubicin
- Where
- 11 sites in Greece
- Volunteers
- 64 people
- Sponsor
- Hellenic Oncology Research Group
Healthy
Safety and Immunogenicity of MSB11455 in Healthy Participants
The primary purpose of this study is to compare the immunogenicity and safety of MSB11455 and Neulasta in healthy adult participants.
- Trial name
- NCT03251339
- Testing
- MSB11455, US-Neulasta
- Where
- 2 sites in New Zealand
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Ovarian Cancer, Epithelial Ovarian Cancer
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05870748
- Testing
- Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine
- Where
- 63 sites in United States, Australia and 5 more
- Volunteers
- 600 people
- Sponsor
- Sutro Biopharma, Inc.
Glioblastoma, Gliosarcoma
Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
Primary objectives To determine maxi tolerated dose of Temodar® in combo w O6-benzylguanine administered for 5 consecutive days in pts w progressive/recurrent GBM To characterize toxicity associated w Temodar® in combo w O6-BG…
- Trial name
- NCT00612989
- Testing
- Temodar and O6-Benzylguanine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Pharmacokinetics, Pharmacodynamics
PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants
Cohorts of Japanese participants will be enrolled and treated prior to cohorts of Caucasian participants for the sake of matching.
- Trial name
- NCT02306915
- Testing
- lipegfilgrastim
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merckle GmbH
Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, and rituximab) in NHL.
- Trial name
- NCT00333008
- Testing
- Doxil, Cyclophosphamide, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- The Alvin and Lois Lapidus Cancer Institute
Breast Neoplasms, Chemotherapy-Induced Febrile Neutropenia
Efficacy and Safety Study With MYL-1401H and Neulasta
This is a Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and Neulasta (Pegfilgrastim) in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy.
- Trial name
- NCT02467868
- Testing
- MYL-1401H, Neulasta
- Where
- 36 sites in Bulgaria, Georgia and 4 more
- Volunteers
- 193 people
- Sponsor
- Mylan Inc.
Breast Cancer
Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer
This study aims to compare the response of triple-negative breast cancer with deficient homologous recombination to intensified alkylating chemotherapy versus standard chemotherapy with dose dense AC and/or Docetaxel-Capecitabine.
- Trial name
- neo-TN (NCT01057069)
- Testing
- Carboplatin and Paclitaxel, Doxorubicin, cyclophosphamide, Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide
- Where
- 14 sites in Netherlands
- Volunteers
- 310 people
- Sponsor
- The Netherlands Cancer Institute
Lymphoma
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
RATIONALE: Herpesvirus is found in the cancer cells of patients with primary effusion lymphoma. Antiviral drugs, such as zidovudine and valganciclovir, may be able to act against the herpesvirus in the cancer cells to help kill…
- Trial name
- NCT00217503
- Testing
- bevacizumab, filgrastim, pegfilgrastim
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia…
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma
- Trial name
- NCT03136146
- Testing
- Bortezomib, Clofarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Triple Negative Breast Cancer
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
This is a Phase Ib/II study assessing the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), recommended Phase 2 dose (RP2D), and efficacy of L-NMMA when combined with docetaxel in refractory locally advanced or…
- Trial name
- NCT02834403
- Testing
- L-NMMA, Docetaxel, Amlodipine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The Methodist Hospital Research Institute
Sarcoma
Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
This is a Phase Ib/II experimental, open-label, dose escalation, active treatment study designed to determine the safety, tolerability, and recommended dose of the combination.
- Trial name
- GemTax (NCT01879085)
- Testing
- Docetaxel, Gemcitabine, Vorinostat
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Melissa Burgess, MD